Rapid & Actionable Precision Therapy Insights –Driven by Data, Guided by Experts
The field of oncology faces several challenges that impact the effective utilization of targeted therapies. The rapidly changing landscape of cancer research, identification of new targetable mutations and advances in targeted treatments complicate the situation, making it difficult for healthcare providers to stay current with new developments. Additionally, the complexity of genomic data can make it challenging for oncologists to accurately interpret results and apply them to treatment decisions. The limited capacity and lack of widespread availability of molecular tumor boards also contributes to delays for the patient. Accessibility to expert opinions is key to ensure that the promise of precision medicine is fully realized for oncology practices and their patients.
Clarified Precision Medicine’s scalable asynchronous Molecular Tumor Board utilizes a medical practice backed by a proven technology platform to interpret genomic tumor profiling testing based on NCCN guidelines. Our expert medical group, backed by state-of-the-art AI, delivers a key last-line review of recommended therapies.
It’s simple and seamless to integrate Clarified’s results to clinical workflow and patient journey. The result: patients benefit from precision therapies with speed and confidence.
In the United States, there are 18 million patients with a history of cancer and 1.9 million new cancer diagnoses each year. Patients who receive precision therapies have survival rates that are three times greater than those who do not. However, 75 percent of doctors say they need help interpreting genomic tests. Now, with Clarified Precision Medicine, any oncologist can be a precision medicine provider, quickly and simply.
Multiple studies have shown that precision oncology in advanced cancer patients not only improves overall survival, but also reduces weekly healthcare costs.
A greater than 50% increase in clinical recommendation of an appropriate targeted therapy
Clarified’s solutions lead to a more than 50 percent increase in the clinical recommendation of targeted therapies in appropriate patients. By providing robust, data-driven insights, Clarified supports pharmaceutical companies in optimizing the identification of actionable mutations and the use of targeted therapies to improve patient outcomes.
Clarified lowers costs (20X+ ROI) with improved outcomes by introducing standardization across precision oncology
Clarified lowers cancer care costs and provides payers and patients a very significant return on investment (ROI) while helping clinicians deliver the best care possible. Our platform’s ability to streamline and standardize care leads to improved outcomes and cost savings for payers, making it a valuable asset in managing oncology expenses while delivering patients the best care possible.
Clarified causes providers to change what they prescribe in 30% of cases, and drives efficiency (time savings of up to 1 hr per patient)
A Clarified expert consult and report results in providers changing their prescribing practices in 30 percent of cases, leading to more accurate and effective treatment decisions. Additionally, our platform drives efficiency, saving up to one hour per patient by integrating genomic insights into the workflow and reducing the time spent on manual data interpretation. Results are delivered within hours so that an individualized treatment approach can be implemented as quickly as possible.
Clarified drives appropriate, guidelines-based NGS test utilization from 18% to 80% in just 3 months
Clarified enhances the utilization of guidelines-based next-generation sequencing (NGS) tests, increasing appropriate use from 18 percent to 80 percent of patients in just three months. This rapid improvement in test utilization ensures that patients receive not only the most relevant and effective diagnostic evaluations, but that the results of their tests drive optimal therapy.
The right treatment at the right time, 100% of the time
With Clarified’s support, patients benefit from receiving the right treatment at the right time, 100 percent of the time. Our platform ensures that every patient’s treatment plan is delivered quickly — often within hours — and is based on the most accurate and comprehensive genomic data available, leading to optimal care outcomes.
1
CLARIFIEDSELECT© provides expert-reviewed treatment options based on a patient’s individual tumor profile - somatic, germline, or liquid. This product helps physicians identify the most effective targeted therapies tailored to the unique genetic profile of each patient, ensuring personalized and precision-based treatment plans.
2
ONCOGUARDIAN© offers comprehensive pharmacogenomics guidance on gene-to-drug interactions for managing risk, including options for managing pain, depression, and anxiety, as well as extreme toxicity management. This product is designed to improve patient quality of life and provide holistic care throughout the treatment journey.
3
CLARIFIEDDATA© enhances the value and marketability of existing clinical resources by providing deep insights and data analysis. This product supports the discovery of new trends and opportunities in oncology, enabling healthcare providers labs, and life science partners to leverage clinical data more effectively.
4
Clarified offers programmatic support to develop and sustain in-house Precision Medicine Tumor Boards. This service helps institutions build and maintain their own tumor board programs, ensuring that they have the necessary resources and expertise to provide high-quality, precision-based oncology care.
The process begins with Clarified’s guidance on selecting the appropriate panel or test for each patient. Our platform provides oncologists with expert recommendations on which next-generation sequencing (NGS) panels to order based on the patient’s clinical presentation and medical history. This initial step ensures that the most relevant genomic information is obtained, setting the stage for effective treatment planning.
Clarified selected as one of a small cohort of companies at the forefront of healthcare innovation leveraging AI and UX to reshape the future.
Immersive cohort-based Rock Health program supports and amplifies the work of visionary healthcare leaders.
(Archive →)
New collaboration will focus on analyzing and improving guidelines-based utilization of precision medicine to better support oncologists and cancer patients.
Learn More →(Archive →)
This partnership, aimed at making precision medicine more accessible for patients and community oncologists, is actively supporting clinicians at Alabama Cancer Care.
Learn More →(Archive →)
This article from the AJMC – The American Journal of Managed Care captures how we’re solving the last mile in precision medicine for clinicians and patients. Our unique combination of artificial intelligence (AI) and medical expertise makes the difference.
Learn More →(Archive →)
Avestria Ventures invested in Clarified Precision Medicine because the company fills a critical oncology need with an advanced solution and, in the process, bridges the gap between genomic testing and care, making genomically-informed precision medicine available, accessible, and actionable.
Learn More →(Archive →)
Clarified Precision Medicine on Tuesday said it has raised $1.2 million in a seed financing round, which it will put toward advancing its virtual molecular tumor board model and help more patients and providers gain access to guidelines-based precision oncology treatments.
Learn More →(Archive →)Founded by leaders in medical oncology, oncology pharmacy, data science and molecular pathology, Clarified Precision Medicine has cultivated a network of expert providers who collectively bring more than 100 years of experience in the application of precision oncology and have built successful programs at universities, communities and integrated health systems.
Board Member
447 Sutter St., Suite 405 PMB13,
San Francisco, CA 94108
435.288.0640
